Director/PDMR Shareholding
Diaceutics PLC
PDMR/PCA Shareholdings & TR-1 Notifications
New York, Belfast and London, 13 November 2026 - Diaceutics PLC (AIM: DXRX) (“Diaceutics” or the “Company”), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, announces that it has been notified that on 12 November 2026:
- Delia Keeling, a person closely associated with Peter Keeling, Chair of Diaceutics, sold 1,750,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 190 pence per Ordinary Share.
- Peter Keeling, Chair of Diaceutics, sold 1,750,000 Ordinary Shares at a price of 190 pence per Ordinary Share. As a result of the sale, Peter and Delia Keeling's combined shareholding in Diaceutics is 11,752,049 Ordinary Shares representing approximately 13.78% of the Company's issued share capital.
- Robyn Keeling, a person closely associated with Ryan Keeling, Chief Executive Officer of Diaceutics, sold 100,000 Ordinary Shares at a price of 190 pence per Ordinary Share.
- Ryan Keeling, Chief Executive Officer of Diaceutics, sold 500,000 Ordinary Shares at a price of 190 pence per Ordinary Share. As a result of the sale, Ryan and Robyn Keeling's combined shareholding in Diaceutics is 2,390,643 Ordinary Shares representing approximately 2.80% of the Company's issued share capital.
- Jordan Clark, Chief Customer Officer of Diaceutics, sold 250,000 Ordinary Shares at a price of 190 pence per Ordinary Share. As a result of the sale, Jordan Clark’s shareholding in Diaceutics is 333,468 Ordinary Shares representing approximately 0.39% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer |
Tel: +44 (0)28 9040 6500 |
|
Nick Roberts, Chief Financial Officer |
investorrelations@diaceutics.com |
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7253 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
|
|
About Diaceutics
At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||||||
|
a. |
Name |
Delia Keeling | |||||
|
2 |
Reason for notification |
| |||||
|
a. |
Position/Status |
PCA to Peter Keeling, Chair | |||||
|
b. |
Initial notification/ Amendment |
Initial | |||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
|
a. |
Name |
Diaceutics PLC | |||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 | |||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
|
b. |
Nature of the transaction |
Sale | |||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
| |
|
|
Price(s) |
Volume(s) |
| ||||
|
£1.90 |
1,750,000 |
| |||||
|
| |||||||
|
d. |
Date of the transaction |
12 November 2026 | |||||
|
e. |
Place of the transaction |
AIM Market of the London Stock Exchange | |||||
|
|
|
|
|
|
|
|
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||||||
|
a. |
Name |
Peter Keeling | |||||
|
2 |
Reason for notification |
| |||||
|
a. |
Position/Status |
Chair | |||||
|
b. |
Initial notification/ Amendment |
Initial | |||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
|
a. |
Name |
Diaceutics PLC | |||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 | |||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
|
b. |
Nature of the transaction |
Sale | |||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
| |
|
|
Price(s) |
Volume(s) |
| ||||
|
£1.90 |
1,750,000 |
| |||||
|
| |||||||
|
d. |
Date of the transaction |
12 November 2026 | |||||
|
e. |
Place of the transaction |
AIM Market of the London Stock Exchange | |||||
|
|
|
|
|
|
|
|
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||||||
|
a. |
Name |
Robyn Keeling | |||||
|
2 |
Reason for notification |
| |||||
|
a. |
Position/Status |
PCA to Ryan Keeling, Chief Executive Officer | |||||
|
b. |
Initial notification/ Amendment |
Initial | |||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
|
a. |
Name |
Diaceutics PLC | |||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 | |||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
|
b. |
Nature of the transaction |
Sale | |||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
| |
|
|
Price(s) |
Volume(s) |
| ||||
|
£1.90 |
100,000 |
| |||||
|
| |||||||
|
d. |
Date of the transaction |
12 November 2026 | |||||
|
e. |
Place of the transaction |
AIM Market of the London Stock Exchange | |||||
|
|
|
|
|
|
|
|
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||||||
|
a. |
Name |
Ryan Keeling | |||||
|
2 |
Reason for notification |
| |||||
|
a. |
Position/Status |
Chief Executive Officer | |||||
|
b. |
Initial notification/ Amendment |
Initial | |||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
|
a. |
Name |
Diaceutics PLC | |||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 | |||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
|
b. |
Nature of the transaction |
Sale | |||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
| |
|
|
Price(s) |
Volume(s) |
| ||||
|
£1.90 |
500,000 |
| |||||
|
| |||||||
|
d. |
Date of the transaction |
12 November 2026 | |||||
|
e. |
Place of the transaction |
AIM Market of the London Stock Exchange | |||||
|
|
|
|
|
|
|
|
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||||||
|
a. |
Name |
Jordan Clark | |||||
|
2 |
Reason for notification |
| |||||
|
a. |
Position/Status |
Chief Customer Officer | |||||
|
b. |
Initial notification/ Amendment |
Initial | |||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
|
a. |
Name |
Diaceutics PLC | |||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 | |||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
|
b. |
Nature of the transaction |
Sale | |||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
| |
|
|
Price(s) |
Volume(s) |
| ||||
|
£1.90 |
250,000 |
| |||||
|
| |||||||
|
d. |
Date of the transaction |
12 November 2026 | |||||
|
e. |
Place of the transaction |
AIM Market of the London Stock Exchange | |||||
|
|
|
|
|
|
|
|
|
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS | ||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: |
Diaceutics PLC ORD GBP0.002 | |||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
|
Non-UK issuer |
| |||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
|
An acquisition or disposal of voting rights |
X | |||||
|
An acquisition or disposal of financial instruments |
| |||||
|
An event changing the breakdown of voting rights |
| |||||
|
Other (please specify) iii: |
| |||||
|
3. Details of person subject to the notification obligation iv | ||||||
|
Name |
Peter Keeling | |||||
|
City and country of registered office (if applicable) |
NA | |||||
|
4. Full name of shareholder(s) (if different from 3.) v | ||||||
|
Name |
| |||||
|
City and country of registered office (if applicable) |
| |||||
|
5. Date on which the threshold was crossed or reached vi: |
12 November 2026 | |||||
|
6. Date on which issuer notified: |
12 November 2026 | |||||
|
7. Total positions of person(s) subject to the notification obligation | ||||||
|
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer (8.A + 8.B) vii | ||
|
Resulting situation on the date on which threshold was crossed or reached |
13.78% |
0.33% |
14.11% |
12,034,517 | ||
|
Position of previous notification (if applicable) |
17.88% |
0.33% |
18.21% |
15,534,517 | ||
|
|
|
|
|
|
|
|
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
|
8 A: Voting rights attached to shares | |||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rights ix |
% of voting rights | |||||||
|
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
Direct (DTR5.1) |
Indirect (DTR5.2.1) | ||||||
|
Ordinary share of £0.002 (GB00BJQTGV64)
|
5,626,025 |
6,126,024 |
6.60% |
7.18% | |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
SUBTOTAL 8. A |
11,752,049 |
13.78% | |||||||
|
| |||||||||
|
8 B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
|
|
SUBTOTAL 8. B 1 |
|
| |||||
|
| |||||||||
|
8 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash Settlement xii |
Number of voting rights |
% of voting rights | ||||
|
Employee share option |
17/04/27 |
17/04/23 to 17/04/27 |
£1.265 per share |
180,000 |
0.21% | ||||
|
Employee share option |
18/05/30 |
18/05/26 to 18/05/30 |
£0.002 per share |
102,468 |
0.12% | ||||
|
|
|
|
|
|
| ||||
|
|
|
|
SUBTOTAL 8.B.2 |
282,468 |
0.33% | ||||
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii |
| |||
|
Full chain of controlled undertakings through which the voting rights and/or the |
X | |||
|
Name xv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold | |
|
Peter Keeling |
6.60% |
0.33% |
6.93% | |
|
Delia Keeling |
7.18% |
-% |
7.18% | |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
| ||||
|
10. In case of proxy voting, please identify: | ||||
|
Name of the proxy holder |
| |||
|
The number and % of voting rights held |
| |||
|
The date until which the voting rights will be held |
| |||
|
| ||||
|
11. Additional information xvi | ||||
|
| ||||
|
|
|
|
|
|
|
Place of completion |
AIM Market of the London Stock Exchange |
|
Date of completion |
13 November 2026 |
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS | ||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: |
Diaceutics PLC ORD GBP0.002 | |||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
|
Non-UK issuer |
| |||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
|
An acquisition or disposal of voting rights |
X | |||||
|
An acquisition or disposal of financial instruments |
| |||||
|
An event changing the breakdown of voting rights |
| |||||
|
Other (please specify) iii: |
| |||||
|
3. Details of person subject to the notification obligation iv | ||||||
|
Name |
Ryan Keeling | |||||
|
City and country of registered office (if applicable) |
NA | |||||
|
4. Full name of shareholder(s) (if different from 3.) v | ||||||
|
Name |
| |||||
|
City and country of registered office (if applicable) |
| |||||
|
5. Date on which the threshold was crossed or reached vi: |
12 November 2026 | |||||
|
6. Date on which issuer notified: |
12 November 2026 | |||||
|
7. Total positions of person(s) subject to the notification obligation | ||||||
|
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer (8.A + 8.B) vii | ||
|
Resulting situation on the date on which threshold was crossed or reached |
2.80% |
1.92% |
4.72% |
4,031,566 | ||
|
Position of previous notification (if applicable) |
3.51% |
1.92% |
5.43% |
4,631,566 | ||
|
|
|
|
|
|
|
|
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
|
8 A: Voting rights attached to shares | |||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rights ix |
% of voting rights | |||||||
|
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
Direct (DTR5.1) |
Indirect (DTR5.2.1) | ||||||
|
Ordinary share of £0.002 (GB00BJQTGV64)
|
2,390,643 |
|
2.80% |
| |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
SUBTOTAL 8. A |
2,390,643 |
2.80% | |||||||
|
| |||||||||
|
8 B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
|
|
SUBTOTAL 8. B 1 |
|
| |||||
|
| |||||||||
|
8 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash Settlement xii |
Number of voting rights |
% of voting rights | ||||
|
Employee share option |
17/04/27 |
17/04/23 to 17/04/27 |
£1.265 per share |
180,000 |
0.21% | ||||
|
Employee share option |
18/05/30 |
18/05/26 to 18/05/30 |
£0.002 per share |
93,407 |
0.11% | ||||
|
Employee share option |
23/07/31 |
23/07/27 to 23/07/31 |
£0.002 per share |
236,250 |
0.28% | ||||
|
Employee share option |
24/10/29 |
24/10/24 to 24/10/29 |
£0.002 per share |
557,953 |
0.65% | ||||
|
Employee share option |
22/07/32 |
22/07/28 to 22/07/2032 |
£0.002 per share |
271,688 |
0.32% | ||||
|
Employee share option |
23/10/33 |
23/10/29 to 23/10/2033 |
£0.002 per share |
301,625 |
0.35% | ||||
|
|
|
|
SUBTOTAL 8.B.2 |
1,640,923 |
1.92% | ||||
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii |
X | |||
|
Full chain of controlled undertakings through which the voting rights and/or the |
| |||
|
Name xv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold | |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
| ||||
|
10. In case of proxy voting, please identify: | ||||
|
Name of the proxy holder |
| |||
|
The number and % of voting rights held |
| |||
|
The date until which the voting rights will be held |
| |||
|
| ||||
|
11. Additional information xvi | ||||
|
| ||||
|
|
|
|
|
|
|
Place of completion |
AIM Market of the London Stock Exchange |
|
Date of completion |
13 November 2026 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE